Thanks, Alan. Market developments, as we have noted for some time now from a state market perspective, we continue to see divergence in performance and dynamics with new markets experiencing high growth, while some mature markets become increasingly competitive, especially after the extended period of price compression and the challenges in competing with the illicit markets that we have highlighted in past calls. For example, as we noted in our last call, 2023 saw strong rollouts for adult-use sales in Missouri and Maryland, both of which also benefited from cross border purchasing by residents in neighboring states with either a medical use only program or no program at all. In fact, from July, 2023 through June, 2024, Maryland's first year total adult-use cannabis sales topped $1.1 billion and Missouri's annual regulated cannabis sales for 2023 totaled over $1.3 billion. Ohio, which legalized adult-use in November began issuing operational licenses for adult-use cannabis cultivation last month. Ohio was expected to be one of the fastest growing markets in the near future and follows on the heels of very successful adult-use introductions in Missouri and Maryland. As we have discussed on other calls, while New York has struggled since adoption of its adult-use program, we are seeing some level of turnaround in the New York regulated market. With the increased pace of licensed dispensary openings for the adult-use program, an increase in enforcement on stores operating illicitly. Regulated sales in New York have increased from about $150 million for all of 2023 to over $260 million in the first six months of 2024. While this progress and the associated increase in regulated sales as welcome, this still represents just a fraction of the NYS Office of Cannabis Management's projection for the regulated cannabis industry in New York to generate $4.2 billion in revenue annually with 63,000 jobs. With regard to state level legislative developments, I would also like to provide a further update from our prior call on two other states that are in the running for adoption of adult-use programs in the near term, Florida and Pennsylvania. In Florida, we continue to monitor support levels for Amendment three, which is expected to appear on the November ballot to legalize adult-use cannabis. While the threshold for approval of the measure is 60% recent polling from Florida politics and Fox News has support above that threshold. And just last month, the Libertarian Party of Florida announced its support of the initiative. In Pennsylvania, lawmakers have been signaling that a bill to legalize Marijuana could be advanced shortly with an added sense of urgency as more neighboring states markets come online like Ohio. Lawmakers also touted a recent study conducted by advocacy organization, responsible PA in consultation with FTI consulting, which estimated that the state could generate upwards of $1.7 billion to $2.8 billion in adult-use sales in the first year of rollout alone, creating an estimated 26,250 to 44,500 jobs for Pennsylvanians. Capital raising and M&A. From a capital raising and M&A perspective, the regulated cannabis industry continues to be challenged that we are seeing some recent encouraging developments. According to Meridian, the regulated cannabis cultivation and retail operators closed on 44 capital raises for approximately $870 million year-to-date through July 19th, with both the number of capital raises, and total amount raised down over 40% from the prior year’s period. M&A for regulated operators for that same time period appeared no better with the total number and dollar amount of M&A transactions down 37% and 66% from the prior year’s period, respectively. That said, we are seeing signs of more acceptance in the debt markets for MSO refinancing, most notably evidenced by our tenant Ascends recent closing on a private placement of $235 million of senior secured notes due in 2029, representing the first MSO to raise more than $100 million in debt since 2022. Federal legislation. From the federal perspective we're of course tracking closely the DEA's progress for rescheduling cannabis from schedule one to schedule three. Process-wise, the DEA received tens of thousands of submissions through late July during the public comment period on its rescheduling proposal. The process from here is hardly clear and a large part up to the discretion of the federal government, which could include DEA responses to certain of these comments and or holding an administrative hearing before any potential final rule is published in the Federal Register. If and when such a final rule is published, it's then subject to a 30-day period for opponents to file suit against the move, which could also serve to significantly delay or altogether prevent the final rule from taking effect. While we remain optimistic on rescheduling, they remain some very significant hurdles, and if rescheduling occurs, there's a great deal of uncertainty as to when that may actually happen. I would like to now turn the call over to Ben to discuss our investment and leasing activity in Q2 in year-to-date. Ben?